Biorasi has completed subject visits under Part A in a rare disease nephropathy study during the peak of the COVID-19 outbreak.
Biorasi is proud to announce the start of a second COVID-19 clinical trial for 2020. The trial will be executed in Russia and Ukraine and will focus on the efficacy of prophylaxis medication for maintaining the health and safety of healthcare personnel treating patients with the coronavirus.
Biorasi is proud to announce the initiation of the company’s first COVID-19 clinical trial in May 2020. The U.S.-based trial will focus on the treatment for lung injuries caused by the COVID-19 virus.
Dr. Kurt Gehlsen, Chief Scientific Officer and Vice President of Medical and Scientific Affairs, has been appointed to the COVID-19 Rapid Response Funding panel at Science Foundation Ireland (SFI).
In observance of Rare Disease Day 2020, Biorasi, LLC held a company-wide event and fundraiser to raise awareness for Angelman Syndrome. The company contributed over $4,000 to the Foundation for Angelman Syndrome Therapeutics. Read more about the highlights of this event >>
Biorasi, LLC and its Board of Directors are proud to announce the appointment of Chris O’Brien to the position of Chief Executive Officer (CEO). O’Brien will assume day-to-day leadership of Company operations, working closely with the Biorasi leadership team to deliver cutting-edge solutions for clinical research project management.
Celebrated Industry Veteran to Lead Scientific, Medical, and Regulatory Affairs at Biorasi
Miami, FL, Jan 29, […]
Biorasi has a solid track record of experience in dermatology, and our goal for this year […]
Florida-Based CRO seeks to expand offerings, global footprint, and headcount after successful investment transaction.
Biorasi, a leading […]
Leading Florida-based Contract Research Organization Partners With University to Train Tomorrow’s Medical Research Professionals
Miami, FL, Aug. […]
Mobile phone apps and wearable devices have a lot of potential to improve clinical studies. However, […]